IL2 and colorectal cancer: The first clinical trials using ACT were pioneered by Rosenberg et al., who used lymphokine-activated killer cells (LAK cells), which consisted of interleukin (IL)-2 activated autologous peripheral blood mononuclear cells, along with high doses of IL-2, for the treatment of tumors such as melanoma or colorectal cancer [11].